M83427 M8 Ruling Active

The tariff classification of Acamprosate Calcium (CAS-77337-73-6), Cisatracurium Besylate (CAS-96946-42-8) and Duloxetine Hydrochloride (CAS-136434-34-9), imported in bulk form, from Spain and Italy

Issued May 17, 2006 by U.S. Customs and Border Protection.

Tariff classification

HTS codes: 2924.19.1050, 2934.99.3000, 2933.49.2600

Headings: 2924, 2934, 2933

Product description

The first product, Acamprosate Calcium, is indicated for the treatment of alcohol dependency. The second product, Cisatracurium Besylate, is a skeletal muscle relaxant administered intravenously. The third product, Duloxetine Hydrochloride, is indicated for the treatment of depression.

CBP rationale

The applicable subheading for Acamprosate Calcium, imported in bulk form, will be 2924.19.1050, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Acyclic amides (including acyclic carbamates) and their derivatives; salts thereof: Other: Amides: Other. The applicable subheading for Cisatracurium Besylate, imported in bulk form, will be 2933.49.2600, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing in the structure a quinoline or isoquinoline ring (whether or not hydrogenated), not further fused: Other: Other Drugs: Other. The applicable subheading for Duloxetine Hydrochloride, imported in bulk form, will be 2934.99.3000, HTSUS, which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: aromatic or modified aromatic: Other: Drugs.

Full text

NY M83427 May 17, 2006 CLA-2-29:RR:NC:2:238 M83427 CATEGORY: Classification TARIFF NO.: 2924.19.1050; 2933.49.2600; 2934.99.3000 Ms. Inge Forstenzer Ren-Pharm International, Ltd. 350 Jericho Turnpike, Suite 204 Jericho, NY 11753 RE: The tariff classification of Acamprosate Calcium (CAS-77337-73-6), Cisatracurium Besylate (CAS-96946-42-8) and Duloxetine Hydrochloride (CAS-136434-34-9), imported in bulk form, from Spain and Italy Dear Ms. Forstenzer: In your letter dated May 2, 2006, you requested a tariff classification ruling. The first product, Acamprosate Calcium, is indicated for the treatment of alcohol dependency. The second product, Cisatracurium Besylate, is a skeletal muscle relaxant administered intravenously. The third product, Duloxetine Hydrochloride, is indicated for the treatment of depression. The applicable subheading for Acamprosate Calcium, imported in bulk form, will be 2924.19.1050, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Acyclic amides (including acyclic carbamates) and their derivatives; salts thereof: Other: Amides: Other.” Pursuant to General Note 13, HTSUS, the rate of duty will be free. The applicable subheading for Cisatracurium Besylate, imported in bulk form, will be 2933.49.2600, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing in the structure a quinoline or isoquinoline ring (whether or not hydrogenated), not further fused: Other: Other Drugs: Other.” Pursuant to General Note 13, HTSUS, the rate of duty will be free. The applicable subheading for Duloxetine Hydrochloride, imported in bulk form, will be 2934.99.3000, HTSUS, which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: aromatic or modified aromatic: Other: Drugs.” Pursuant to General Note 13, HTSUS, the rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at: www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Searching CBP rulings the smart way

TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.

Book a demo →